BNP Paribas Asset Management
NTLA icon

BNP Paribas Asset Management’s Intellia Therapeutics NTLA Stock Holding History

BNP Paribas Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.1K Sell
1,956
-17
-0.9% -$238 ﹤0.01% 1917
2026
Q1 		$25.3K Buy
1,973
+551
+39% +$7.02K ﹤0.01% 1954
2025
Q4 		$13K Buy
1,422
+511
+56% +$7.03K ﹤0.01% 2073
2025
Q3 		$16K Buy
911
+106
+13% +$1.31K ﹤0.01% 1475
2025
Q2 		$8K Buy
+805
New +$6.61K ﹤0.01% 1855

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

BNP Paribas Asset Management's NTLA Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Intellia Therapeutics (NTLA) stake by 0.86% in Q2 2026, selling an estimated $238 and leaving 1,956 shares worth $33.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1917.

BNP Paribas Asset Management first reported a position in NTLA in Q2 2025 and has held it in 5 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • BNP Paribas Asset Management held 1,956 shares of Intellia Therapeutics worth $33.1K as of Q2 2026.
  • BNP Paribas Asset Management sold 17 Intellia Therapeutics shares in Q2 2026, an estimated $238.
  • Intellia Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1917 holding.
  • BNP Paribas Asset Management first reported a position in Intellia Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.